Browse online courses and resources on Lung Cancer.

All Lung Cancer Courses
Collapse 2018 Webinar Course: Immunotherapy for the Treatment of Lung Cancer and irAE Management (Advances in Cancer Immunotherapy™)

aci17-sitc-clr.jpg

From the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) educational series, this course provides an overview on cancer immunotherapy for the treatment of melanoma and immune related adverse event management. The on-demand webinar, hosted by Drs. Hwu (University of MD Anderson Cancer Center), Cascone (University of Texas MD Anderson Cancer Center) and, registered nurse, Michelle Rohlfs (University of Texas MD Anderson Cancer Center), gives an update on immunotherapy for the treatment of lung cancers and immune related adverse event management. Stay up to date with the most recent clinical recommendations and research by exploring the curated Additional Resources tab. 

 

 

Target Audience

The target audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians, allied health professionals, other patient care providers, students and patient advocates. The course is designed to help all members of the cancer health care team stay connected with updates in the field of cancer immunotherapy. 

 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 

Course Available Beginning: February 19, 2019

Original Course Date: January 31, 2019
MORE INFOMORE INFO 2018 Webinar Course: Immunotherapy for the Treatment of Lung Cancer and irAE Management (Advances in Cancer Immunotherapy™)
Collapse 2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells.  The course also provides the latest in immunotherpy treatment for lung cancer and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment.  After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy for lung cancer and how to identify and manage common side effects of immunotherapy agents. 

 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Benjamin Levy, MD

Clinical Director, SKCC at Sibley

Johns Hopkins

 

Ticiana Leal, MD

Assistant Professor 

UW Carbone Cancer Center

 

Educational Objectives

After completing this activity, the participant should be able to:

  • Implement cancer immunotherapy treatment for lung cancer.
  • Identify the appropriate clinical management of common side effects of immunotherapy agents.
  • Describe the rationale for common approaches to cancer immunotherapy.

 


SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


 

Continuing Education Information

 

Credit Available: January 28, 2019 - January 28, 2020

Approximate Time to Complete:  45 minutes

 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

sitc_log_color.png PIM_logo.png

 

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
 

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.

(Universal Activity Number - JA4008162-9999-19-603-H01-P)

Type of Activity: Knowledge


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is .8 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

Faculty
Benjamin Levy, MD - Consulting Fees: AstraZeneca, Celgene, Eli Lilly, Genentech, Merck,Takeda

Ticiana Leal, MD - Consulting Fees: AbbVie, AstraZeneca, BMS, Novartis, Takeda 


Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Tara Withington, CAE, Executive Director of SITC has an ownership interest as a partner at Executive Director, Inc. 


Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period January 28, 2019 through January 28, 2020  participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

  1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
  2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
  3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
  4. Complete the post-test and survey.
  5. Click Process Credit.
  6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

 

Original Course Date: January 28, 2019

Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO 2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Deepa Rangachari, MD

    Instructor, Medicine, Harvard Medical School

    Beth Israel Deaconess Medical Center

     

    Educational Objectives

    After completing this activity, the participant should be better able to:

    • Discuss the clinical data on the efficacy and mechanism of action of approved therapies

    • Recognize patient selection criteria for approved therapies

    • Describe appropriate dosing and sequencing therapies

    • Identify the appropriate clinical management of common side effects of immunotherapy agents

    •  Implement cancer immunotherapy for the treatment of lung cancers

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of naive NSCLC patients

    • Explain the role of biomarkers associated with response or lack of response to immunotherapy including PD-L1, tumor mutational burden (TMB), and epidermal growth factor receptor (EGFR)


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-728-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Deepa Rangachari, MD: No conflict of interest to report.

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse Advances in Cancer Immunotherapy™ 2017 Video Series: Immunotherapy for the Treatment of Lung Cancer

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are used as content for online courses. One video has been selected for each topic of the 2017 ACI program (twelve total modules).

     

    The online modules will facilitate understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments; strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting; and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.

     

    Target Audience

    These modules have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Availabe: Oct. 6, 2017- September 30, 2018

     

    Other Available Modules

    Module 1: Basic Principles of Cancer Immunotherapy

    Module 2: Immunotherapy for the Treatment of Melanoma

    Module 3: Immunotherapy for the Treatment of Lung Cancer

    Module 4: Immunotherapy for the Treatment of Genitourinary Cancers

    Module 5: Immunotherapy for the Treatment of Hematologic Malignancies

    Module 6: Immunotherapy for the Treatment of Head and Neck Cancers

    Module 7: Effective Practices for Incorporating Immunotherapy into Hospital Operations 

    Module 8: Coverage and Reimbursement Challenges and Strategies

    Module 9: Mechanisms of Immune-Related Adverse Events

    Module 10: Nursing Perspective on irAEs: Patient Education, Monitoring and Management 

    Module 11: Management and Mitigation of irAEs for Immunotherapy Prescribers 

    Module 12: Identification and Management of Immune-Related Adverse Events in the Emergency Setting

    Original Course Date: October 06, 2017
    MORE INFOMORE INFO Advances in Cancer Immunotherapy™ 2017 Video Series: Immunotherapy for the Treatment of Lung Cancer
    Collapse Advancing the Care of Patients with SCLC: Emerging Treatment Options

    Access Course

     

    Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: Dec. 18, 2018- Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ABIM: 0.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Advancing the Care of Patients with SCLC: Emerging Treatment Options
    Collapse Debates and Dilemmas, Part 2: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom

    Access Course

     

    Debates and Dilemmas, Part 2: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in WhomExperts discuss 2 cases on second-line management of advanced NSCLC with immune checkpoint inhibitors.

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses. 

     

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 31st, 2019- Jan. 31st, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: January 31, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Debates and Dilemmas, Part 2: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom
    Collapse Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for  oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 9, 2018- Nov. 9, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 09, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?
    Collapse Lung Cancer Treatment: Talking to All Your Healthcare Providers

    Access Course

     

    883529-fig1.jpgThis article is for people with advanced lung cancer, care partners, and others who want to learn about talking to their healthcare providers about lung cancer treatment with immunotherapy.

     

    You will learn:

    - Why and how talking with all of your healthcare providers helps

    - Your role in helping your cancer care providers and others to work as a team

    - What medical information to share and how to keep it in order

    - Questions to ask your healthcare providers

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 7, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 07, 2017
    MORE INFOMORE INFO Lung Cancer Treatment: Talking to All Your Healthcare Providers
    Collapse Practice Your Skills: Managing Patients with Advanced NSCLC

    Access Course

     

    Practice Your Skills: Managing Patients With Advanced NSCLCApply best practices to assess, treat, and educate patients with advanced NSCLC.

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

    The goal of this activity is to build physician confidence in identifying and ordering appropriate evidence-based treatment regimens and providing patient education.

     

     

     

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: Dec. 13, 2018- Dec. 13, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 13, 2018

    Approved Credit:
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Practice Your Skills: Managing Patients with Advanced NSCLC
    Collapse When Is Immunotherapy Right for My Lung Cancer?

    Access Course

     

    885207-fig1.pngThis article is for people with non-small cell lung cancer (NSCLC), their care partners, and others who want to learn about immunotherapy for the condition. The goal is to understand why and when immunotherapy might be right for you.

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 23, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 23, 2017
    MORE INFOMORE INFO When Is Immunotherapy Right for My Lung Cancer?